Antibiotic resistance and its cost: is it possible to reverse resistance?
暂无分享,去创建一个
[1] G. Eliopoulos,et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. , 2004, The Journal of infectious diseases.
[2] D. Sandvang,et al. Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections , 2005, Antimicrobial Agents and Chemotherapy.
[3] H. Juan. Small Colony Variants: a Pathogenic Form of Bacteria that Facilitates Persistent and Recurrent Infections , 2009 .
[4] Cecilia Dahlberg,et al. Amelioration of the cost of conjugative plasmid carriage in Eschericha coli K12. , 2003, Genetics.
[5] O. Berg,et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Guay. Contemporary Management of Uncomplicated Urinary Tract Infections , 2012, Drugs.
[7] O. Sahin,et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] P. Bennett,et al. Rifampicin resistance and its fitness cost in Enterococcus faecium. , 2004, The Journal of antimicrobial chemotherapy.
[9] M. Lipsitch,et al. Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] S. Schrag,et al. Reducing antibiotic resistance , 1996, Nature.
[11] D. Andersson,et al. The Fitness Cost of Streptomycin Resistance Depends on rpsL Mutation, Carbon Source and RpoS (σS) , 2009, Genetics.
[12] F. Claverie-Martin,et al. Glycopeptide resistance in enterococci. , 2000, International microbiology : the official journal of the Spanish Society for Microbiology.
[13] J. Mcgowan. Minimizing Antimicrobial Resistance in Hospital Bacteria: Can Switching or Cycling Drugs Help? , 1986, Infection Control.
[14] F. M. Stewart,et al. The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] Andreas Handel,et al. The Role of Compensatory Mutations in the Emergence of Drug Resistance , 2006, PLoS Comput. Biol..
[16] D. Andersson,et al. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. , 2005, The Journal of antimicrobial chemotherapy.
[17] A. Robicsek,et al. The worldwide emergence of plasmid-mediated quinolone resistance. , 2006, The Lancet. Infectious diseases.
[18] I. Chopra,et al. Genetic Basis of Resistance to Fusidic Acid in Staphylococci , 2007, Antimicrobial Agents and Chemotherapy.
[19] M G Reynolds,et al. Compensatory evolution in rifampin-resistant Escherichia coli. , 2000, Genetics.
[20] B. Spratt,et al. Antibiotic resistance: Counting the cost , 1996, Current Biology.
[21] M. Bidochka,et al. Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size. , 1998, Canadian journal of microbiology.
[22] Jonathan D. Cryer,et al. Time Series Analysis , 1986 .
[23] S. Gillespie,et al. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? , 2005, The Journal of antimicrobial chemotherapy.
[24] M. Skurnik,et al. Erythromycin Resistance Genes in Group A Streptococci in Finland , 1999, Antimicrobial Agents and Chemotherapy.
[25] D. Hughes,et al. Genetic Determinants of Resistance to Fusidic Acid among Clinical Bacteremia Isolates of Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[26] Lotte Lambertsen,et al. Mini-Tn7 transposons for site-specific tagging of bacteria with fluorescent proteins. , 2004, Environmental microbiology.
[27] R. Wise. Antimicrobial resistance: priorities for action. , 2002, The Journal of antimicrobial chemotherapy.
[28] D. Andersson,et al. Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium , 1999, Molecular microbiology.
[29] C. Fishwick,et al. Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques , 2004, Antimicrobial Agents and Chemotherapy.
[30] C. Fishwick,et al. Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical Prevalence , 2006, Antimicrobial Agents and Chemotherapy.
[31] T. Wichelhaus,et al. Compensatory Adaptation to the Loss of Biological Fitness Associated with Acquisition of Fusidic Acid Resistance in Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[32] D. Andersson,et al. Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis , 2004, Antimicrobial Agents and Chemotherapy.
[33] O. Berg,et al. Biological Costs and Mechanisms of Fosfomycin Resistance in Escherichia coli , 2003, Antimicrobial Agents and Chemotherapy.
[34] J. Frère,et al. Cytosolic Intermediates for Cell Wall Biosynthesis and Degradation Control Inducible β-Lactam Resistance in Gram-Negative Bacteria , 1997, Cell.
[35] J. Daurès,et al. Impact of infection control interventions and antibiotic use on hospital MRSA: a multivariate interrupted time-series analysis. , 2007, International journal of antimicrobial agents.
[36] D. Rouse,et al. Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. , 1998, The Journal of infectious diseases.
[37] G Kahlmeter,et al. Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. , 2010, The Journal of antimicrobial chemotherapy.
[38] M. Blaser,et al. Persistence of Resistant Staphylococcus epidermidis after Single Course of Clarithromycin , 2005, Emerging infectious diseases.
[39] Ted Cohen,et al. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. , 2003, The Lancet. Infectious diseases.
[40] M. Blaser,et al. Long-Term Persistence of Resistant Enterococcus Species after Antibiotics To Eradicate Helicobacter pylori , 2003, Annals of Internal Medicine.
[41] N. Woodford,et al. Infections caused by Gram-positive bacteria: a review of the global challenge. , 2009, The Journal of infection.
[42] S. Eriksson,et al. Fusidic Acid-Resistant Mutants of Salmonella enterica Serovar Typhimurium with Low Fitness In Vivo Are Defective in RpoS Induction , 2003, Antimicrobial Agents and Chemotherapy.
[43] S. Cole,et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis , 1997, Infection and immunity.
[44] D. Livermore,et al. Enhancement of host fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. , 2004, The Journal of antimicrobial chemotherapy.
[45] Y. Arakawa,et al. Growth Competition of Macrolide‐Resistant and ‐Susceptible Helicobacter pylori Strains , 2004, Microbiology and immunology.
[46] T. Wilson,et al. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis , 1995, Molecular microbiology.
[47] H. Nikaido. Multidrug resistance in bacteria. , 2009, Annual review of biochemistry.
[48] G. Swedberg,et al. Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli , 1997, Journal of bacteriology.
[49] I. Chopra,et al. Characterization of the Epidemic European Fusidic Acid-Resistant Impetigo Clone of Staphylococcus aureus , 2007, Journal of Clinical Microbiology.
[50] C. D. Long,et al. The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.
[51] D. Hughes,et al. Genetic and Phenotypic Identification of Fusidic Acid-Resistant Mutants with the Small-Colony-Variant Phenotype in Staphylococcus aureus , 2007, Antimicrobial Agents and Chemotherapy.
[52] D. Farrell,et al. Heterogeneous Macrolide Resistance and Gene Conversion in the Pneumococcus , 2006, Antimicrobial Agents and Chemotherapy.
[53] O. Berg,et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Cantón. Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[55] C. Walsh,et al. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. , 1991, Biochemistry.
[56] D. Hughes,et al. Hyper-susceptibility of a fusidic acid-resistant mutant of Salmonella to different classes of antibiotics. , 2005, FEMS microbiology letters.
[57] R. Anderson,et al. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[58] Ted Cohen,et al. Isoniazid resistance and the future of drug-resistant tuberculosis. , 2004, Microbial drug resistance.
[59] Lars Liljas,et al. Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium , 2002, Molecular microbiology.
[60] Valeria Souza,et al. Stress-Induced Mutagenesis in Bacteria , 2003, Science.
[61] S. Gudmundsson,et al. Clonal spread of resistant pneumococci despite diminished antimicrobial use. , 2002, Microbial drug resistance.
[62] B. Levin,et al. Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.
[63] Carl T. Bergstrom,et al. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[64] A. Sundsfjord,et al. Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci in the absence of antibiotic selection in vitro and in gnotobiotic mice. , 2002, Microbial drug resistance.
[65] S. Nyberg,et al. Association between Antimicrobial Consumption and Resistance in Escherichia coli , 2008, Antimicrobial Agents and Chemotherapy.
[66] P. E. Kopp,et al. Superspreading and the effect of individual variation on disease emergence , 2005, Nature.
[67] E. Böttger,et al. Fitness of antibiotic-resistant microorganisms and compensatory mutations , 1998, Nature Medicine.
[68] K. Francis,et al. Real-Time In Vivo Bioluminescent Imaging for Evaluating the Efficacy of Antibiotics in a Rat Staphylococcus aureus Endocarditis Model , 2005, Antimicrobial Agents and Chemotherapy.
[69] D. Ince,et al. Quinolone Resistance Due to Reduced Target Enzyme Expression , 2003, Journal of bacteriology.
[70] M. Arthur,et al. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147 , 1992, Journal of bacteriology.
[71] P. Laippala,et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] G. Jacoby,et al. Quinolone resistance from a transferable plasmid , 1998, The Lancet.
[73] P Huovinen,et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.
[74] D. Hughes,et al. Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness , 2009, PLoS pathogens.
[75] Zaid Abdo,et al. Combining Mathematical Models and Statistical Methods to Understand and Predict the Dynamics of Antibiotic-Sensitive Mutants in a Population of Resistant Bacteria During Experimental Evolution , 2004, Genetics.
[76] K. Johnson. An Update. , 1984, Journal of food protection.
[77] B. Levin,et al. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. , 2000, Genetics.
[78] J. E. Bouma,et al. Effects of segregation and selection on instability of plasmid pACYC184 in Escherichia coli B , 1987, Journal of bacteriology.
[79] P M Bennett,et al. Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. , 2005, The Journal of antimicrobial chemotherapy.
[80] Dykes,et al. Fitness costs associated with class IIa bacteriocin resistance in Listeria monocytogenes B73 , 1998, Letters in applied microbiology.
[81] R. Anderson,et al. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[82] Diarmaid Hughes,et al. Gene amplification and adaptive evolution in bacteria. , 2009, Annual review of genetics.
[83] D. Briles,et al. Relative Fitness of Fluoroquinolone-resistant Streptococcus pneumoniae , 2005, Emerging infectious diseases.
[84] F. Ausubel,et al. Caenorhabditis elegans: a model genetic host to study Pseudomonas aeruginosa pathogenesis. , 2000, Current opinion in microbiology.
[85] D. Livermore,et al. Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. , 2005, The Journal of antimicrobial chemotherapy.
[86] Kshitij D Modi,et al. Noninvasive Monitoring of Pneumococcal Meningitis and Evaluation of Treatment Efficacy in an Experimental Mouse Model* , 2005, Molecular imaging.
[87] M. Pai,et al. Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis , 2008, Annals of Internal Medicine.
[88] T. Wichelhaus,et al. Biological Cost of Rifampin Resistance from the Perspective of Staphylococcus aureus , 2002, Antimicrobial Agents and Chemotherapy.
[89] P. Small,et al. Effect of drug resistance on the generation of secondary cases of tuberculosis. , 2003, The Journal of infectious diseases.
[90] T. Wichelhaus,et al. Molecular analysis of fusidic acid resistance in Staphylococcus aureus , 2003, Molecular microbiology.
[91] G. Eliopoulos,et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. , 2004, The Journal of antimicrobial chemotherapy.
[92] B. Levin,et al. The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.
[93] P. Courvalin,et al. Fitness Cost of VanA-Type Vancomycin Resistance in Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.
[94] N. McCallum,et al. Fitness Cost of SCCmec and Methicillin Resistance Levels in Staphylococcus aureus , 2004, Antimicrobial Agents and Chemotherapy.
[95] D. Hughes,et al. Fusidic Acid-Resistant Mutants of Salmonella enterica Serovar Typhimurium Have Low Levels of Heme and a Reduced Rate of Respiration and Are Sensitive to Oxidative Stress , 2004, Antimicrobial Agents and Chemotherapy.
[96] C E Nord,et al. Effect of antimicrobial agents on the ecological balance of human microflora. , 2001, The Lancet. Infectious diseases.
[97] S. Normark. beta-Lactamase induction in gram-negative bacteria is intimately linked to peptidoglycan recycling. , 1995, Microbial drug resistance.
[98] N. Ward,et al. Priorities for action , 2019, Ready for the Dry Years: Building Resilience to Drought in South-East Asia.
[99] A. Maurelli,et al. Fitness Cost Due to Mutations in the 16S rRNA Associated with Spectinomycin Resistance in Chlamydia psittaci 6BC , 2005, Antimicrobial Agents and Chemotherapy.
[100] D. Andersson,et al. Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus , 2001, Molecular microbiology.
[101] Levin Br. Models for the spread of resistant pathogens. , 2002 .
[102] Clifton E. Barry,et al. Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium tuberculosis , 1996, Science.
[103] O. Berg,et al. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. , 2000, Science.
[104] D. Livermore,et al. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction , 2001, The Lancet.
[105] J. Roth,et al. Accumulation of mutants in “aging” bacterial colonies is due to growth under selection, not stress-induced mutagenesis , 2008, Proceedings of the National Academy of Sciences.
[106] S. Normark,et al. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta‐lactamase induction. , 1994, The EMBO journal.
[107] Hiroshi Nikaido,et al. Efflux-Mediated Drug Resistance in Bacteria , 2012, Drugs.
[108] F. Baquero,et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. , 2002, The Journal of antimicrobial chemotherapy.
[109] D. Andersson,et al. Drug resistance and fitness in Mycobacterium tuberculosis infection. , 2005, The Journal of infectious diseases.
[110] Kshitij D Modi,et al. Noninvasive Biophotonic Imaging for Monitoring of Catheter-Associated Urinary Tract Infections and Therapy in Mice , 2005, Infection and Immunity.
[111] S. Gillespie,et al. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. , 2002, Microbial drug resistance.
[112] Linus Sandegren,et al. Bacterial gene amplification: implications for the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.
[113] O. Cars,et al. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. , 2003, The Journal of antimicrobial chemotherapy.
[114] B. Levin,et al. Minimizing potential resistance: a population dynamics view. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[115] D. Andersson,et al. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium , 2007, Molecular microbiology.
[116] F. Baquero,et al. Biological Cost of AmpC Production forSalmonella enterica Serotype Typhimurium , 2000, Antimicrobial Agents and Chemotherapy.
[117] E. Giraud,et al. Fitness cost of fluoroquinolone resistance in Salmonella enterica serovar Typhimurium. , 2003, Journal of medical microbiology.
[118] B. Levin,et al. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[119] D. Hughes,et al. Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections , 2003, Antimicrobial Agents and Chemotherapy.
[120] G. Church,et al. Functional Characterization of the Antibiotic Resistance Reservoir in the Human Microflora , 2009, Science.
[121] M. Ehrenberg,et al. Fusidic acid‐resistant EF‐G perturbs the accumulation of ppGpp , 2000, Molecular microbiology.
[122] S. Gillespie,et al. Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.
[123] S. Levy,et al. Survival of rifampin-resistant mutants of Pseudomonas fluorescens and Pseudomonas putida in soil systems. , 1988, Applied and environmental microbiology.
[124] Georg Peters,et al. Identification of the Genetic Basis for Clinical Menadione-Auxotrophic Small-Colony Variant Isolates of Staphylococcus aureus , 2008, Antimicrobial Agents and Chemotherapy.
[125] S. Gillespie,et al. Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. , 2000, The Journal of infection.
[126] J. E. Bouma,et al. Evolution of a bacteria/plasmid association , 1988, Nature.
[127] B. Levin. Models for the spread of resistant pathogens. , 2002, The Netherlands journal of medicine.
[128] A. Robicsek,et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase , 2006, Nature Medicine.
[129] A. Liljas,et al. The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants. , 1996, Journal of molecular biology.
[130] K. Kristinsson,et al. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. , 1997, Microbial drug resistance.
[131] R. May,et al. Infectious disease dynamics: What characterizes a successful invader? , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[132] I. Chopra,et al. The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. , 2003, The Journal of antimicrobial chemotherapy.
[133] S. Lindquist,et al. Coordinate regulation of beta-lactamase induction and peptidoglycan composition by the amp operon. , 1991, Science.
[134] D. Andersson,et al. Virulence of antibiotic-resistant Salmonella typhimurium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[135] S. Normark,et al. Components of the peptidoglycan‐recycling pathway modulate invasion and intracellular survival of Salmonella enterica serovar Typhimurium , 2004, Cellular microbiology.
[136] Fernando Baquero,et al. Predicting antibiotic resistance , 2007, Nature Reviews Microbiology.
[137] Andrew R. Francis,et al. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis , 2009, Proceedings of the National Academy of Sciences.
[138] R. Lenski. Quantifying fitness and gene stability in microorganisms. , 1991, Biotechnology.
[139] I. Tubulekas,et al. Suppression of rpsL phenotypes by tuf mutations reveals a unique relationship between translation elongation and growth rate , 1993, Molecular microbiology.
[140] J. McElnay,et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. , 2008, The Journal of antimicrobial chemotherapy.
[141] I. Chopra,et al. Molecular basis of fusB‐mediated resistance to fusidic acid in Staphylococcus aureus , 2006, Molecular microbiology.
[142] E. Böttger,et al. Fitness Cost of Chromosomal Drug Resistance-Conferring Mutations , 2002, Antimicrobial Agents and Chemotherapy.
[143] S. Cole,et al. Effect of katG Mutations on the Virulence of Mycobacterium tuberculosis and the Implication for Transmission in Humans , 2002, Infection and Immunity.
[144] K. Francis,et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. , 2005, The Journal of antimicrobial chemotherapy.